GlassScriptPhysician profile
Nicholas Argento
NPI 1093781155
$1,055,808.80
in general payments reported to CMS, 2019-2025
50 companies · $129K in 2025
The $129K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158K · 2020: $141K · 2021: $141K · 2022: $206K · 2023: $156K · 2024: $126K · 2025: $129K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $189K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $139K · Travel and Lodging: $47K · Consulting Fee: $22K · Food and Beverage: $13K · Education: $73.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $189,397.12 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $139,429.20 |
| Travel and Lodging | $46,883.86 |
| Consulting Fee | $22,067.00 |
| Food and Beverage | $12,789.17 |
| Education | $73.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $385,716.19 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $322,495.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $146,470.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47,791.56 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $33,792.34 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $28,372.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $25,021.52 | 2019-2025 | Afrezza |
| Eli Lilly and Company | $19,683.98 | 2023-2025 | |
| Insulet Corporation | $16,181.85 | 2019-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $14,982.76 | 2019 | |
| Convatec INC. | $8,320.00 | 2019-2023 | |
| Ascensia Diabetes Care US INC. | $1,547.66 | 2021-2023 | |
| Zealand Pharma US, INC. | $814.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $754.90 | 2022-2025 | |
| Senseonics, Incorporated | $450.00 | 2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $323.15 | 2019-2025 | Repatha, Repatha, Tepezza |
| Abbott Laboratories | $313.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $304.36 | 2021-2025 | |
| Abbvie INC. | $291.09 | 2019-2025 | Synthroid |
| Beta Bionics, INC. | $288.83 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $271.92 | 2022-2025 | Korlym |
| Antares Pharma, INC. | $218.80 | 2019-2025 | Xyosted |
| Radius Health, INC. | $174.39 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $164.74 | 2022-2025 | Strensiq |
| Sequel Med Tech, LLC | $136.49 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $110.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.63 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $63.60 | 2024-2025 | Unithroid |
| Madrigal Pharmaceuticals | $60.92 | 2025 | Rezdiffra |
| Medtronic, INC. | $51.76 | 2024 | Minimed 780g |
| Cequr Corporation | $44.89 | 2023-2025 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $43.78 | 2024-2025 | |
| Globus Medical, INC. | $42.80 | 2025 | Senza |
| Amarin Pharma, INC. | $41.17 | 2019-2020 | |
| Kyowa Kirin, INC. | $40.57 | 2024-2025 | Crysvita |
| Recordati_rare_diseases_inc. | $39.21 | 2025 | Isturisa |
| Horizon Therapeutics Plc | $36.21 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $33.17 | 2019 | |
| Tolmar, INC. | $29.00 | 2024-2025 | Jatenzo |
| Chiesi USA, INC. | $28.05 | 2024 | Myalept |
| Almatica Pharma LLC | $24.79 | 2025 | Teriparatide |
| Esperion Therapeutics, INC. | $23.96 | 2025 | Nexletol |
| Ibsa Pharma INC. | $21.74 | 2023 | Tirosint, Licart |
| Lifescan, INC. | $21.34 | 2022 | |
| Grt US Holding, INC. | $18.60 | 2022 | |
| Halozyme INC | $18.03 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $17.51 | 2024 | |
| Acella Pharmaceuticals, LLC | $14.29 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $13.24 | 2024 | Contrave |
| Companion Medical, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Argento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.